Common GLP-1s available in Canada (as of 2025) include: *T irzepatide is dual-acting (GIP + GLP-1), which sets it apart pharmacologically but places it in the same broader category of incretin-based therapies
Reporting helps build the national evidence base for drug safety and can contribute to future updates of the medicine's side effect profile
Concurrently, there is a downregulation in the expression of components of voltage-gated potassium channels, which normally regulate neuronal excitability, repolarization, and frequency of action potentials
Wojtkowiak JW, Fouad F, LaLonde DT, Kleinman MD, Gibbs RA, Reiners JJ Jr, et al
Allowing peptide sales while blocking the primary payment method would create an untenable user experience and compliance nightmare